Adalimumab for sight-threatening uveitis in Behçet's disease

Mushtaq, Bushra; Saeed, Tariq; Situnayake, R D; Murray, Philip I.

doi:10.1038/sj.eye.6702352

Cited by 148 publications

(77 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In those patients, adalimumab was effective in maintaining disease remission and visual acuity in patients who had to switch due to difficulty in attending infusions (three patients) [Mushtaq et al 2007], anaphylactoid infusion reaction (one patient) [Takase et al 2011], relapse after discontinuation of infliximab (two patients) or lack of response to infliximab (one patient) [Bawazeer et al 2010].…”

Section: ]mentioning

confidence: 99%

“…Based on case reports [Mushtaq et al 2007;Takase et al 2011;Adan et al 2010] and retrospective case series [Bawazeer et al 2010], adalimumab 40 mg subcutaneously every 2 weeks appears to be effective in BD uveitis. In the largest study published to date regarding the use of adalimumab in ocular BD [Bawazeer et al 2010], 17 out of 21 eyes had improvement of visual acuity by more than three lines.…”

Section: ]mentioning

confidence: 99%

See 1 more Smart Citation

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

115

101

View full text Add to dashboard Cite

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

show abstract

Section: ]mentioning

confidence: 99%

Section: ]mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

115

101

View full text Add to dashboard Cite

show abstract

“…16 Bu ajan›n Behçet hastal›¤›nda intraoküler inflamasyonun kontrolünde baflar›l› oldu¤u bildirilmifltir. [44][45][46] Bawazeer ve Raffa 11 hastalar›n›n 10'unda 4 haftal›k bir tedavi süresince intraoküler inflamasyonun tamamen kontol alt›na al›nabildi¤ini bildirmifllerdir. 46 Ajan›n intraokü-ler inflamasyon d›fl›nda nörolojik, barsak, eklem ve mukoza tutulumlar›nda da çok etkili oldu¤u bildirilmektedir.…”

Section: Tnf Antagonistleriunclassified

New Treatment Alternatives in the Management of Non-İnfectious İntraocular İnflammations: Biologic Agents

Emre¹,

Tutkun²

2011

tjo

View full text Add to dashboard Cite

ÖzetEnfeksiyöz olmayan üveitlerin tedavisinde son y›llara kadar genel olarak immün sistemi bask›layan ilaçlar kullan›lmak-tayd›. Ancak gen mühendisli¤indeki geliflmeler, inflamatuar süreçte yer alan özgün molekülleri hedefleyen proteinlerin sentezini ve bu proteinlerin terapötik olarak kullan›lmalar›n› mümkün k›lm›flt›r. Genel olarak protein yap›s›ndaki bu ajanlar biyolojik ajanlar olarak adland›r›lm›fllard›r. Oftalmologlar›n biyolojik ajanlar ile tecrübeleri s›n›rl› olsa da, bu ajanlar romatoloji ve dermatoloji baflta olmak üzere di¤er disiplinler taraf›ndan yo¤un biçimde kullan›lmaktad›rlar. ‹nterferon, infliksimab ve adalimumab baflta olmak üzere birçok biyolojik ajan›n üveit hastalar›nda kullan›m› ile ilgili literatür verisi olmas›na ra¤men henüz bu endikasyonda ruhsatl› kullan›mlar› yoktur. Ayr›ca bu ajanlar›n kullan›m› s›ras›nda dikkat edilmesi gereken güvenlik önlemleri ve önemli risk faktörleri mevcuttur. Bu derlemenin amac›, dirençli üveit hastalar›nda kullan›labilen biyolojik ajanlar konusunda güncel ve kapsaml› bilgi sunmakt›r. ( SummaryConventional immunosuppressive agents have been traditionally used for the treatment of noninfectious uveitis. Recent developments in genetic engineering have made it possible to synthesize proteins that target specific molecules playing role in the inflammatory response. These agents are generally in protein structure and are named biologic agents. While there is limited experience with biologics in the field of ophthalmology, they are commonly used in other disciplines such as rheumatology and dermatology. Although considerable data have accumulated in the uveitis literature regarding the use of biologic agents, including mainly interferon, infliximab, and adalimumab, their use for this indication is still off-label. Moreover, there are certain precautions that have to be taken into account, as well as important safety issues associated with their use. The purpose of this paper is to present an updated comprehensive review of biologic agents that may be used for the treatment of refractory uveitis. (Turk J Ophthalmol 2011; 41: 243-55 GiriflEnfeksiyöz olmayan üveitlerin tedavisinde kullan›lmakta olan immunsupresan ajanlar, ba¤›fl›kl›k sistemini genel olarak bask›lamakta veya sapt›rmaktad›rlar. Bu tedavi yöntem-lerinin sebep olduklar› ciddi yan etkiler ile tedaviye dirençli olgular, hekimleri yeni tedavi aray›fllar›na itmektedir. Son y›llarda araflt›r›lan biyolojik ajanlar, inflamatuar süreçteki öz-gün molekülleri (proteinleri) etkileyerek ba¤›fl›kl›k sisteminde daha s›n›rl› ancak etkin bir tedavi sa¤lamaktad›rlar. Biyolojik ajanlar, moleküler rekombinant DNA teknolojisi kullan›larak elde edilen proteinlerdir. Bu ajanlar›n büyük ço¤un-lu¤u monoklonal antikorlard›r. fiu an için enfeksiyöz olmayan üveitlerin tedavisinde bafll›ca kullan›lan biyolojik ajanlar 3 grupta s›n›fland›r›labilir; i. Interferon-α, ii. TNF-α antagonistleri ve iii. Çeflitli sitokin veya yüzey membran proteini gibi farkl› hedeflere yönelik antikorlar veya füzyon proteinleri.

show abstract

“…Moreover, AU flares during adalimumab treatment were predominantly mild. Adalimumab has been found to be effective in Behçet's disease in several studies, with clinical remission of and absence of recurrence during treatment [35]. The usefulness of adalimumab is particularly evident for patient showing hypersensitivity to infliximab [36].…”

Section: Adalimumabmentioning

confidence: 99%

Biological agents in the treatment of uveitis

Paroli¹,

Abbouda²,

Abicca³

et al. 2013

ABB

View full text Add to dashboard Cite

Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biological process and therefore defined as "biologics" has been successfully used in the treatment of immunemediated rheumatic diseases. These drugs target different pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in small uncontrolled trials, with general and unexpected efficacy. The present review analyzes the literature on treatment of uveitis with the biologics currently available for the treatment of inflammatory rheumatic diseases. We used PubMed search engine as the main source of information. Among the papers included in the reference list, a particular emphasis was given on articles published during the last 5 years.

show abstract

Adalimumab for sight-threatening uveitis in Behçet's disease

Abstract: Adalimumab appears to maintain disease remission in Behçet's disease.

Cited by 148 publications

References 5 publications

Update on the therapy of Behçet disease

Update on the therapy of Behçet disease

New Treatment Alternatives in the Management of Non-İnfectious İntraocular İnflammations: Biologic Agents

Biological agents in the treatment of uveitis

Contact Info

Product

Resources

About